Lifetime cost-effectiveness of denosumab versus zoledronic for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases (BM): United States managed care perspective.
Michael E. Rader
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Mark Danese
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Ze Cong
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Marc Halperin
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Yi Qian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Carsten Dietrich Goessl
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Karen Chung
Employment or Leadership Position - Amgen
Stock Ownership - Amgen